April 28th - Hedgie Hot Stock

Thursday, 29 Apr 2010 | 5:31 PM ET

What do Greenlight Capital, Blue Ride Capital and T2 Advisors all have in common? They’re all bullish this name.

And according to Anthony Scaramucci of Skybridge Capital, that name is Pfizer .

Yup, you read that right. Boring old Pfizer is our latest hedgie hot stock!

Pfizer Key Stats
-Trailing P/E: 12.2x
-Mean consensus estimate for 2010: $2.17 per share
-Implied forward P/E: 7.6x
-Dividend yield: 4.37%

Hedge Fund Trade of the Week
Why investors should jump in on Pfizer.

Here’s why Scaramucci likes it:
-Cheap Valuation
-Lagging Markets
-Strong Pipeline

The buzz on Pfizer is that the patents are expiring and therefore it doesn’t have earnings growth, explains Scaramucci. But there are exciting developments going on in the industry – such as the Dendreon breakthrough drug - and Pfizer has plenty of cash to make more acquisitions.

Got something to to say? Send us an e-mail at fastmoney-web@cnbc.com and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send those e-mails to fastmoney@cnbc.com.

CNBC.com with wires

  Price   Change %Change

Contact Fast Money

  • Showtimes

    Halftime Report - Weekdays 12p ET
    Fast Money - Weekdays 5p ET
  • Melissa Lee is the host of CNBC's “Fast Money” and “Options Action.”

  • Scott Wapner is host of the "Fast Money Halftime Report," which airs weekdays from 12 p.m. to 1 p.m. ET.

  • Guy Adami is a contributor on CNBC's "Fast Money." He also is managing director of stockMONSTER.com.

  • Najarian, the "Pit Boss," is cofounder of optionMONSTER.com, a news site for options traders.

  • Finerman is president of Metropolitan Capital Advisors, Inc., a company she co-founded.

  • Founder of EmergingMoney.com

  • Chief Market Strategist for Virtus Investment Partners & CNBC Contributor

Halftime Report